Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Can J Cardiol ; 29(12): 1535-52, 2013 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-24267800

RESUMO

Pediatric heart failure (HF) is an important cause of morbidity and mortality in childhood. This article presents guidelines for the recognition, diagnosis, and early medical management of HF in infancy, childhood, and adolescence. The guidelines are intended to assist practitioners in office-based or emergency room practice, who encounter children with undiagnosed heart disease and symptoms of possible HF, rather than those who have already received surgical palliation. The guidelines have been developed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology, and are accompanied by practical Recommendations for their application in the clinical setting, supplemented by online material. This work does not include Recommendations for advanced management involving ventricular assist devices, or other device therapies.


Assuntos
Insuficiência Cardíaca/diagnóstico , Insuficiência Cardíaca/tratamento farmacológico , Adolescente , Algoritmos , Bloqueadores do Receptor Tipo 1 de Angiotensina II/uso terapêutico , Inibidores da Enzima Conversora de Angiotensina/uso terapêutico , Displasia Arritmogênica Ventricular Direita/complicações , Displasia Arritmogênica Ventricular Direita/diagnóstico , Biomarcadores/sangue , Canadá , Cardiomiopatias/complicações , Cardiomiopatias/diagnóstico , Cardiotônicos/uso terapêutico , Catecolaminas/uso terapêutico , Criança , Pré-Escolar , Terapia Combinada , Morte Súbita Cardíaca/etiologia , Morte Súbita Cardíaca/prevenção & controle , Diagnóstico Diferencial , Diuréticos/uso terapêutico , Ecocardiografia , Eletrocardiografia Ambulatorial , Medicina Baseada em Evidências , Cardiopatias Congênitas/diagnóstico , Cardiopatias Congênitas/terapia , Insuficiência Cardíaca/classificação , Insuficiência Cardíaca/etiologia , Humanos , Lactente , Imageamento por Ressonância Magnética , Miocardite/complicações , Miocardite/diagnóstico , Miocárdio/patologia , Prognóstico , Fatores de Risco , Sociedades Médicas , Vasodilatadores/uso terapêutico , Vasopressinas/antagonistas & inibidores
2.
Sci Transl Med ; 3(95): 95ra75, 2011 Aug 10.
Artigo em Inglês | MEDLINE | ID: mdl-21832240

RESUMO

Attention deficit hyperactivity disorder (ADHD) is a common and persistent condition characterized by developmentally atypical and impairing inattention, hyperactivity, and impulsiveness. We identified de novo and rare copy number variations (CNVs) in 248 unrelated ADHD patients using million-feature genotyping arrays. We found de novo CNVs in 3 of 173 (1.7%) ADHD patients for whom we had DNA from both parents. These CNVs affected brain-expressed genes: DCLK2, SORCS1, SORCS3, and MACROD2. We also detected rare inherited CNVs in 19 of 248 (7.7%) ADHD probands, which were absent in 2357 controls and which either overlapped previously implicated ADHD loci (for example, DRD5 and 15q13 microduplication) or identified new candidate susceptibility genes (ASTN2, CPLX2, ZBBX, and PTPRN2). Among these de novo and rare inherited CNVs, there were also examples of genes (ASTN2, GABRG1, and CNTN5) previously implicated by rare CNVs in other neurodevelopmental conditions including autism spectrum disorder (ASD). To further explore the overlap of risks in ADHD and ASD, we used the same microarrays to test for rare CNVs in an independent, newly collected cohort of 349 unrelated individuals with a primary diagnosis of ASD. Deletions of the neuronal ASTN2 and the ASTN2-intronic TRIM32 genes yielded the strongest association with ADHD and ASD, but numerous other shared candidate genes (such as CHCHD3, MACROD2, and the 16p11.2 region) were also revealed. Our results provide support for a role for rare CNVs in ADHD risk and reinforce evidence for the existence of common underlying susceptibility genes for ADHD, ASD, and other neuropsychiatric disorders.


Assuntos
Transtorno do Deficit de Atenção com Hiperatividade/genética , Variações do Número de Cópias de DNA/genética , Predisposição Genética para Doença , Adolescente , Transtorno Autístico/genética , Estudos de Casos e Controles , Criança , Pré-Escolar , Feminino , Loci Gênicos/genética , Glicoproteínas/genética , Humanos , Masculino , Doenças do Sistema Nervoso/genética , Linhagem , Fatores de Risco , Análise de Sequência de DNA , Fatores de Transcrição/genética , Proteínas com Motivo Tripartido , Ubiquitina-Proteína Ligases
3.
J Biol Chem ; 282(15): 10841-5, 2007 Apr 13.
Artigo em Inglês | MEDLINE | ID: mdl-17307730

RESUMO

Extending the productive lifespan of human cells could have major implications for diseases of aging, such as atherosclerosis. We identified a relationship between aging of human vascular smooth muscle cells (SMCs) and nicotinamide phosphoribosyltransferase (Nampt/PBEF/Visfatin), the rate-limiting enzyme for NAD+ salvage from nicotinamide. Replicative senescence of SMCs was preceded by a marked decline in the expression and activity of Nampt. Furthermore, reducing Nampt activity with the antagonist FK866 induced premature senescence in SMCs, assessed by serial quantification of the proportion of cells with senescence-associated beta-galactosidase activity. In contrast, introducing the Nampt gene into aging human SMCs delayed senescence and substantially lengthened cell lifespan, together with enhanced resistance to oxidative stress. Nampt-mediated SMC lifespan extension was associated with increased activity of the NAD+-dependent longevity enzyme SIRT1 and was abrogated in Nampt-overexpressing cells transduced with a dominant-negative form of SIRT1 (H363Y). Nampt overexpression also reduced the fraction of p53 that was acetylated on lysine 382, a target of SIRT1, suppressed an age-related increase in p53 expression, and increased the rate of p53 degradation. Moreover, add-back of p53 with recombinant adenovirus blocked the anti-aging effects of Nampt. These data indicate that Nampt is a longevity protein that can add stress-resistant life to human SMCs by optimizing SIRT1-mediated p53 degradation.


Assuntos
Senescência Celular/fisiologia , Pentosiltransferases/metabolismo , Sobrevivência Celular , Células Cultivadas , Ativação Enzimática , Humanos , Miócitos de Músculo Liso/citologia , Miócitos de Músculo Liso/enzimologia , NAD/metabolismo , Nicotinamida Fosforribosiltransferase , Estresse Oxidativo , Pentosiltransferases/genética , Proteína Supressora de Tumor p53/genética , Proteína Supressora de Tumor p53/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA